Wyeth Research Alliances
Plexxikon: A research collaboration dedicated to discovering novel therapies for diabetes and metabolic disorders.
Exelixis: A partnership focused on developing therapies that target the farnesoid X receptor (FXR), a nuclear hormone receptor implicated in a variety of metabolic and liver disorders.
Karo Bio: A strategic collaboration aimed at development of new therapies for treatment and prevention of atherosclerosis by targeting the liver X receptor (LXR).
Zealand: A 3-year agreement for the research and development of new GAP junction modifying compounds targeting cardiovascular disorders.
Opsona: A partnership focused on target validation and drug discovery of therapies to treat inflammatory diseases based on Toll-like receptor (TLR) targets.
Elan: Research and development collaboration on immunotherapeutic approaches to treatment and prevention of Alzheimer's disease, and development and commercialization of novel therapeutics for the treatment of sleep disorders.
Neurome: Discovery research collaboration focused on the investigation of neurodegenerative diseases using Neurome's proprietary discovery technologies and expertise in quantitative neuropathology.
Galapagos: The Galapagos Alliance expands Wyeth's Discovery efforts in osteoporosis research with access to a proprietary adenoviral-based, drugable, gene-silencing library.
Trubion: Strategic alliance for the discovery, development, and commercialization of novel biopharmaceutical products utilizing Trubion's proprietary small modular immunopharmaceutical (SMIP™) technology.
DHL: A multiyear strategic agreement for the logistics coordination of global clinical trial materials distribution, focused on improving efficiencies.
Raven: A partnership focused on developing and commercializing selected monoclonal antibody therapeutics (MAbs) to a specified target, using Raven’s proprietary antibody discovery process.
CSL Limited: A license and collaborative agreement for the development of a new generation of human vaccines, using ISCOMATRIX®.
Ablynx: Discovery and development of nanobodies for multiple diseases.
Biotica: Discovery and development of novel rapamycin analogs for multiple disease areas.
Pharmacopeia: Discovery and development of novel JAK3 inhibitors for treatment of inflammatory disorders.
elbion NV : Discovery and development of novel PDE10 inhibitors for treatment of schizophrenia.
Catalyst Biosciences: Access to Alterase™ therapeutics platform for discovery and development of novel therapeutics for metabolic diseases and cancer.
Translational Medicine Research Collaboration (TMRC): Novel industry-academic-government partnership focused on discovery and implementation of biomarkers.
GVK Bio: Small molecule contract research partnership in Wyeth-dedicated facility in Hyderabad, India.
228286-01